MetaStat Inc Completes 500 Breast Cancer Patients Trial

MetaStat Inc (OTC:MTST), a life science company that focuses on treating systemic metastasis, is pleased to announce that it has completed a 500 patient trial in breast cancer.

As quoted in the press release:

According to Dr. Oscar Bronsther, Chief Executive Officer and Chief Medical Officer of MetaStat, “We are thrilled that we have the benefit of having a focused team that is able to systematically and consistently deliver on our strategic vision of bringing the power of our diagnostic platform to patients.”

“This is a validation of our earlier research on this new technology platform,” Warren C. Lau, Founder and President of MetaStat, noted. “We are now another step closer to meeting a critical unmet medical need for breast cancer patients and the physicians who treat them.”

Click here to read the full MetaStat Inc (OTC:MTST) press release.